Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 36Glioblastoma 24Carcinoma, Non-Small-Cell Lung 21Carcinoma, Hepatocellular 15Ovarian Neoplasms 14Brain Neoplasms 14Carcinoma, Renal Cell 13Pancreatic Neoplasms 12Neoplasms 10Neoplasm Metastasis 10Glioma 10Breast Neoplasms 10Colonic Neoplasms 8Astrocytoma 8Melanoma 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Liver Neoplasms 6Gliosarcoma 6Endometrial Neoplasms 6Stomach Neoplasms 5Lung Neoplasms 5Fallopian Tube Neoplasms 5Colorectal Cancer Metastatic 5Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Oligodendroglioma 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Bevacizumab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡